SciBase Holding (SCIB.ST) Stock Analysis & AI Equity Report
SciBase Holding (SCIB.ST) overview
SciBase Holding (SCIB.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, SciBase Holding reported revenue of SEK 40.5m and operating profit of SEK -85.2m; the year-end share price was 28.75 SEK and market capitalisation was SEK 124m. SciBase Holding is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get SciBase Holding's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About SciBase Holding
SciBase Holding AB is a medical technology company focused on dermatology. It develops and commercializes Nevisense and Nevisense Go, point-of-care platforms that use electrical impedance spectroscopy and AI to support detection of melanoma and other skin conditions, as well as skin barrier assessment for research and clinical applications. Disposable electrodes are a key recurring revenue driver.
Generate the SciBase Holding report
SciBase Holding is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for SciBase Holding and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.